Table 3.
Cancer immunotherapy targeting CT antigens in clinical trials.
| Cancer | Detailed Description | Clinical Trial Phase | References (ClinicalTrials.gov Identifier) |
|---|---|---|---|
| Multiple myeloma | MAGE-A3 and NY-ESO-1 (peptide vaccination) combined with chemotherapy and auto transplantation |
Phase II, Phase III | NCT00090493 (https://clinicaltrials.gov/ct2/show/NCT00090493) |
| Stage III or IV melanoma | Melanoma antigen peptides (including NY-ESO-1b analog and MAGE-A10) and Montanide adjuvant | Phase I | NCT00112242 (https://clinicaltrials.gov/ct2/show/NCT00112242) |
| Metastatic melanoma | Autologous DCs transfected with tumour antigen (including MAGE-A3) RNA and proteasome siRNA | Phase I | NCT00672542 (https://clinicaltrials.gov/ct2/show/NCT00672542) |
| Metastatic melanoma and renal cell cancer | Chemotherapy followed by anti-NY-ESO-1 T-cell receptor gene engineered lymphocytes | Phase II | NCT00670748 (https://clinicaltrials.gov/ct2/show/NCT00670748) |
| Melanoma | MAGE-A3 plusGSK2132231A (antigen-specific cancer immunotherapy) | Phase III(failed) | NCT00796445 (https://clinicaltrials.gov/ct2/show/NCT00796445) |
| NY-ESO-1- expressing tumours |
CpG 7909/ Montanide in combination with NY-ESO-1 peptide or protein |
Phase I | NCT00819806 (https://clinicaltrials.gov/ct2/show/NCT00819806) |
| Melanoma (expressing NY-ESO-1) |
Topical Resiquimod as an adjuvant for NY-ESO-1 protein, plus Montanide vaccination | Phase I | NCT00821652 (https://clinicaltrials.gov/ct2/show/NCT00821652) |
| Melanoma | NY-ESO-1 protein and TLR3 agonist adjuvant | Phase I, Phase II | NCT01079741 (https://clinicaltrials.gov/ct2/show/NCT01079741) |
| NSCLC | Chemotherapy and DEXs (peptides like MAGEs and NY-ESO-1 pulsed onto DC) |
Phase II | NCT01159288 (https://clinicaltrials.gov/ct2/show/NCT01159288) |
| Neuroblastoma and sarcoma | Mature DC pulsed with peptides derived from NY-ESO-1, MAGE-A1, and MAGE-A3, preceded by chemotherapy | Phase I | NCT01241162 (https://clinicaltrials.gov/ct2/show/NCT01241162) |
| Metastatic cutaneous melanoma | NY-ESO-1 plus GSK2241658A (antigen-specific cancer immunotherapy) |
Phase I | NCT01213472 (https://clinicaltrials.gov/ct2/show/NCT01213472) |
| Myeloma | MAGE-A3 immunization with adjuvant Hiltonol plus activated autologous T cells | Phase II | NCT01245673 (https://clinicaltrials.gov/ct2/show/NCT01245673) |
| Hodgkin’s or non-Hodgkin’s lymphoma | CTL primed against tumour-associated antigens, including MAGE-A4 and NY-ESO-1 | Phase I(ongoing) | NCT01333046 (https://clinicaltrials.gov/ct2/show/NCT01333046) |
| Synovial sarcoma | Genetically engineered NY-ESO-1-specific T cells with chemotherapy | Phase I | NCT01343043 (https://clinicaltrials.gov/ct2/show/NCT01343043) |
| Multiple myeloma | Autologous T cells expressing high affinity, TCR-specific for NY-ESO-1 | Phase II | NCT01352286 (https://clinicaltrials.gov/ct2/show/NCT01352286) |
| Stage IIB–IV resected melanoma | Recombinant MAGE-A3 protein combined with immunological adjuvant system | Early Phase I | NCT01425749 (https://clinicaltrials.gov/ct2/show/NCT01425749) |
| NY-ESO-1- expressing solid tumours |
CD205-NY-ESO-1 fusion protein with or without sirolimus | Phase I | NCT01522820 (https://clinicaltrials.gov/ct2/show/NCT01522820) |
CT: cancer/testis; MAGE: melanoma-associated antigen; DC: dendritic cell; TLR: toll-like receptor; NSCLC: non-small-cell lung carcinoma; DEX: dendritic cell-derived exosome; CTL: cytotoxic T lymphocyte; CD: cluster of differentiation.